首页> 外文OA文献 >Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance

【2h】

Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance

机译：目前的吸烟对表皮生长因子受体（EGFR）的存活产生了不利影响，并促进的淋巴瘤激酶（ALK）阴性先进的非鳞状非小细胞肺癌（NSCLC）患者治疗，患者治疗培养基继续维护

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Liping Lin; Juanjuan Zhao; Jiazhu Hu; Guorong Zou; Fuxi Huang; Jianjun Han; Yan He; Xiaolong Cao;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance [J] . Liping Lin, Juanjuan Zhao, Jiazhu Hu, Journal of Cancer . 2018,第12期

机译：目前的吸烟对表皮生长因子受体（EGFR）的存活产生了不利影响，并促进的淋巴瘤激酶（ALK）阴性先进的非鳞状非小细胞肺癌（NSCLC）患者治疗，患者治疗培养基继续维护
2. Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials [J] . Martin Connock, Xavier Armoiry, Alexander Tsertsvadze, BMC Cancer . 2019,第1期

机译：目前授权的第二次或第三线治疗表皮生长因子受体（EGFR）的比较存活率和促进淋巴瘤激酶（ALK）阴性先进或转移性非小细胞癌：对试验的系统审查和次要分析
3. A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer [J] . Gallacher Daniel, Auguste Peter, Royle Pamela, Clinical drug investigation . 2019,第12期

机译：对经济评估的系统审查，评估了用于先前经过治疗的表皮生长因子受体（EGFR）和促进淋巴瘤激酶（ALK）阴性晚期/转移性非小细胞肺癌的持牌药物的成本效益
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance [O] . Liping Lin, Juanjuan Zhao, Jiazhu Hu, 2018

机译：当前吸烟对培美曲塞持续维持治疗的表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK）阴性的晚期非鳞状非小细胞肺癌（NSCLC）患者的生存有不利影响
7. Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials [O] . Martin Connock, Xavier Armoiry, Alexander Tsertsvadze, 2019

机译：目前授权的第二次或第三线治疗表皮生长因子受体（EGFR）的比较存活率和促进淋巴瘤激酶（ALK）阴性先进或转移性非小细胞癌：对试验的系统审查和次要分析

Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance

著录项

引文网络

相似文献

相关主题

期刊订阅